Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on oncology, immunology, and neuroscience research and development. Founded in 1919, Ono has become one of Japan's leading innovative pharmaceutical companies.

Overview

Ono Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on oncology, immunology, and neuroscience research and development. Founded in 1919, Ono has become one of Japan's leading innovative pharmaceutical companies.

Overview

Ono Pharmaceutical has evolved into a major Japanese drug developer with significant partnerships with global pharmaceutical companies. The company operates research facilities in Japan and maintains collaborations with leading academic institutions worldwide["@onoa"].

Funding

• IPO: 1950s (TSE: 4568)
• Market Cap: ~$15B (2026)

Corporate Highlights

• Founded: 1919
• Headquarters: Osaka, Japan
• Employees: Approximately 6,000
• TSE: 4568
• Market Cap: Approximately $15 billion USD

History and Development

Founded (1919)

Expansion (1950s-1990s)

• Expanded into prescription pharmaceuticals
• Established research laboratories
• Developed strong cardiovascular and gastrointestinal portfolios

Innovation Era (2000s-Present)

• Focused on innovative drug development
• Built strong oncology pipeline
• Established global partnerships
• Developed Opdivo (nivolumab), one of the world's first PD-1 inhibitors

Key Partnerships

Bristol-Myers Squibb (BMS)

• Ono discovered nivolumab and retained rights in Japan, Korea, and Taiwan
• BMS acquired global rights outside these territories
• The partnership has expanded to include multiple combination therapies
• Opdivo is one of the world's best-selling cancer drugs[@opdivo2016]

Pfizer

• Co-development of oncology candidates
• Combination therapy development
• Global clinical trial collaboration

AstraZeneca

• Cardiovascular and metabolic diseases collaboration
• Research partnerships in inflammation

Pipeline and Programs

Neuroscience Programs

| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| ONO-4474 | TREM2](/proteins/trem2) | Alzheimer's disease | Phase 1 |
| ONO-4686 | Tau | Alzheimer's disease | Preclinical |
| ONO-8809 | Undisclosed | CNS disorders | Phase 1 |
| ONO-2910 | Undisclosed | Migraine | Phase 2 |

Oncology Programs (Key)

| Drug Candidate | Target | Indication | Stage |
|---------------|--------|------------|-------|
| Opdivo (Nivolumab) | PD-1 | Multiple cancers | Approved |
| Yervoy (Ipilimumab) | CTLA-4 | Melanoma, others | Approved |
| ONO-4538 | PD-1 | Various tumors | Approved |
| ONO-7914 | LAG-3 | Solid tumors | Phase 1 |

Neurological Relevance

Ono's neuroscience pipeline includes significant programs for neurodegenerative diseases[@onob]:

TREM2 Antibodies (ONO-4474)

• TREM2 is expressed on microglia in the brain
• Genetic variants increase Alzheimer's disease risk
• Antibodies may enhance microglia function and clear amyloid
• Phase 1 trials evaluating safety and pharmacokinetics

Tau Targeting (ONO-4686)

• Anti-tau antibodies may block tau spread between neurons
• Complements amyloid-targeted approaches
• Addresses neurofibrillary tangles
• Preclinical development ongoing

BACE Inhibitors (Discontinued)

• ONO-4485 reached Phase 2 development
• Discontinued in 2018 due to liver toxicity in clinical trials
• Reflects challenges in Alzheimer's drug development - safety concerns with BACE inhibition[@bace]

Research Focus Areas

• [Neuroinflammation](/mechanisms/neuroinflammation) in neurodegeneration
• [Microglia](/cell-types/microglia) biology and modulation
• Blood-brain barrier penetration strategies
• Novel antibody engineering for CNS delivery

Science and Technology

Antibody Engineering

• Monoclonal antibody discovery
• Antibody humanization
• Bispecific antibody platforms
• Antibody-drug conjugates

Immunology Focus

• Checkpoint inhibitors (PD-1, CTLA-4, LAG-3)
• Immuno-oncology combinations
• Cytokine modulators

Financial Highlights (2024)

• Revenue: Approximately $3.5 billion USD (500 billion JPY)
• R&D Investment: Approximately $800 million USD (120 billion JPY)
• Market Cap: Approximately $15 billion USD (2 trillion JPY)
• Opdivo Royalty Income: Significant contributor to revenue

Global Presence

• Japan: Headquarters and primary market
• US: Clinical development operations
• Europe: Research partnerships
• Asia: Regional partnerships in Korea and Taiwan
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [TREM2](/proteins/trem2-protein)](/mechanisms/trem2)
• [Tau Protein](/proteins/tau)
• [Microglia](/cell-types/microglia)
• [Bristol-Myers Squibb](/companies/bristol-myers)
• Opdivo
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [PD-1 Signaling](/genes/gnal)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References